NCT02646800终止4 期
A Multi-center, Open-label, Non-comparative Study to Evaluate the Safety and Efficacy of Micafungin Against Fungal Infections Caused by Candida Spp or Aspergillus Spp
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 终止
- 入组人数
- 105
- 主要终点
- Safety as assessed by overall incidence and severity of adverse events for patients with candidiasis
研究概览
简要总结
The objective of this study is to evaluate the safety and efficacy of intravenous micafungin for the treatment of adult patients in China infected by Candida spp or Aspergillus spp.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients who are diagnosed as proven/probable/possible fungal infection caused by Candida or Aspergillus based on the Chinese guidelines
- •Females of childbearing potential must have a negative pregnancy test within 48 hrs prior to the study and reliable methods of contraception should be started 4 weeks prior to and during the whole study.
- •Patients capable to understand the purposes and risks of the study, who are willing and able to participate in the study and from whom written and dated informed consent to participate in the study is obtained.
- •Failure to fulfill inclusion criteria in another study, is not necessarily an exclusion criteria for this study, assuming other inclusion criteria 1-4 stated above are fulfilled.
排除标准
- •Patient has history of hypersensitivity, or any serious reaction to any component of this product or other echinocandins.
- •Subject is unlikely to comply with the visits scheduled in the protocol in the opinion of investigator or has a history of non-compliance.
- •Pregnant women, nursing mothers, lactating women, and women of child-bearing potential who are unwilling to use reliable contraception for the duration of the study and for 6 weeks following completion of the study.
- •AST/ALT > 5 times the upper limit of normal (ULN)
- •Total bilirubin> 2.5 times ULN
- •Patient has been previously enrolled in this study.
研究组 & 干预措施
Micafungin group
Experimental
Intravenous (IV)
干预措施: Micafungin (Drug)
结局指标
主要结局
Safety as assessed by overall incidence and severity of adverse events for patients with candidiasis
时间窗: Up to a maximum of 10 weeks
Safety as assessed by overall incidence and severity of adverse events for patients with aspergillosis
时间窗: Up to a maximum of 14 weeks
Safety as assessed by adverse reactions for patients with candidiasis
时间窗: Up to a maximum of 10 weeks
Safety as assessed by adverse reactions for patients with aspergillosis
时间窗: Up to a maximum of 14 weeks
次要结局
- Safety as assessed by relationship of adverse events to Micafungin for patients with aspergillosis(Day 1 to the end of treatment (up to 6 weeks, and up to 12 weeks for refractory patients))
- Safety as assessed by liver and kidney function for patients with candidiasis(Day 1 to the end of treatment (up to 4 weeks, and up to 8 weeks for patients with chronic disseminated candidiasis, candida osteomyelitis, or candida endocarditis))
- Clinical Improvement rate for patients with candidiasis(End of treatment (up to up to 4 weeks, and up to 8 weeks for patients with chronic disseminated candidiasis, candida osteomyelitis, or candida endocarditis)
- Clinical Improvement rate for patients with aspergillosis(End of treatment (up to 6 weeks, and up to 12 weeks for refractory patients))
- Fungal clearance rate for patients with candidiasis(End of treatment (up to 4 weeks, and up to 8 weeks for patients with chronic disseminated candidiasis, candida osteomyelitis, or candida endocarditis))
- Overall success rate for patients with candidiasis(End of treatment (up to up to 4 weeks, and up to 8 weeks for patients with chronic disseminated candidiasis, candida osteomyelitis, or candida endocarditis))
- Fungal clearance rate for patients with aspergillosis(End of treatment (up to 6 weeks, and up to 12 weeks for refractory patients)
- Fatality rate for patients with candidiasis(End of treatment (up to 4 weeks, and up to 8 weeks for patients with chronic disseminated candidiasis, candida osteomyelitis, or candida endocarditis))
- Overall success rate for patients with aspergillosis(End of treatment (up to 6 weeks, and up to 12 weeks for refractory patients))
- Fatality rate for patients with aspergillosis(End of treatment (up to 6 weeks, and up to 12 weeks for refractory patients)
- Safety as assessed by relationship of adverse events to Micafungin for patients with candidiasis(Day 1 to the end of treatment (up to 4 weeks, and up to 8 weeks for patients with chronic disseminated candidiasis, candida osteomyelitis, or candida endocarditis))
- Safety as assessed by liver and kidney function for patients with aspergillosis(Day 1 to the end of treatment (up to 6 weeks, and up to 8 weeks, and up to 12 weeks for refractory patients))
研究者
相似试验
终止
4 期
Post Marketing Study to Evaluate the Efficacy and Safety of Micafungin Treatment on Invasive AspergillosisInvasive AspergillosisNCT02646774Astellas Pharma China, Inc.43
终止
3 期
Comparative Study of Micafungin (FK463) Versus Placebo as Prophylactic Antifungal Therapy in the ICUInvasive Fungal InfectionsNCT00048750Astellas Pharma Inc104
终止
4 期
A Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Candidiasis or CandidemiaCandidemiaCandidiasisNCT01982071Astellas Pharma China, Inc.59
已完成
不适用
A Retrospective Study Evaluating the Efficacy and Safety of Micafungin Sodium in the Treatment of Invasive Fungal InfectionsInvasive Fungal InfectionsNCT02678598Astellas Pharma China, Inc.2,555
终止
2 期
Trial of Micafungin (FK463) in Combination With Liposomal Amphotericin B (AmBisome) for AspergillosisAspergillosisNCT00047827Astellas Pharma Inc2